KR100862178B1 - 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물 - Google Patents

라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물 Download PDF

Info

Publication number
KR100862178B1
KR100862178B1 KR1020037013090A KR20037013090A KR100862178B1 KR 100862178 B1 KR100862178 B1 KR 100862178B1 KR 1020037013090 A KR1020037013090 A KR 1020037013090A KR 20037013090 A KR20037013090 A KR 20037013090A KR 100862178 B1 KR100862178 B1 KR 100862178B1
Authority
KR
South Korea
Prior art keywords
cancer
gemcitabine
delete delete
cci
fluorouracil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037013090A
Other languages
English (en)
Korean (ko)
Other versions
KR20040007491A (ko
Inventor
기봉스제임스조셉쥬니어
듀카트게리
프리슈유르겐헤르만에른스트
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20040007491A publication Critical patent/KR20040007491A/ko
Application granted granted Critical
Publication of KR100862178B1 publication Critical patent/KR100862178B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020037013090A 2001-04-06 2002-04-05 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물 Expired - Fee Related KR100862178B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28238801P 2001-04-06 2001-04-06
US28238501P 2001-04-06 2001-04-06
US60/282,385 2001-04-06
US60/282,388 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (2)

Publication Number Publication Date
KR20040007491A KR20040007491A (ko) 2004-01-24
KR100862178B1 true KR100862178B1 (ko) 2008-10-09

Family

ID=26961412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037013090A Expired - Fee Related KR100862178B1 (ko) 2001-04-06 2002-04-05 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물

Country Status (21)

Country Link
EP (1) EP1385551B1 (https=)
JP (1) JP2004525950A (https=)
KR (1) KR100862178B1 (https=)
CN (1) CN1309421C (https=)
AT (1) ATE406892T1 (https=)
AU (1) AU2007242958A1 (https=)
BR (1) BR0208627A (https=)
CA (1) CA2442849A1 (https=)
DE (1) DE60228699D1 (https=)
EA (1) EA010184B1 (https=)
ES (1) ES2312568T3 (https=)
HU (1) HUP0304093A3 (https=)
IL (1) IL157898A0 (https=)
MX (1) MXPA03009092A (https=)
NO (1) NO20034433L (https=)
NZ (1) NZ540047A (https=)
PL (1) PL363991A1 (https=)
PT (1) PT1385551E (https=)
SG (1) SG152906A1 (https=)
SI (1) SI1385551T1 (https=)
WO (1) WO2002080975A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
PL409579A1 (pl) * 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
GB0124577D0 (en) * 2001-10-12 2001-12-05 Novartis Forschungsstiftung Novel methods
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP1732583A4 (en) * 2004-02-26 2009-08-12 Penn State Res Found COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS
WO2006027545A2 (en) * 2004-09-10 2006-03-16 Agency For Science, Technology And Research Method
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
JP2009514870A (ja) * 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
RU2487711C2 (ru) * 2005-11-21 2013-07-20 Новартис Аг Лечение нейроэндокринных опухолей
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
EP1996193A2 (en) 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
WO2007143212A1 (en) * 2006-06-02 2007-12-13 Ariad Gene Therapeutics, Inc. Capecitabine combination therapy
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CA2683109A1 (en) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
WO2008109163A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
JP5579057B2 (ja) 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN105147713A (zh) 2008-08-04 2015-12-16 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA
SI3687996T1 (sl) 2017-09-27 2022-04-29 Incyte Corporation Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
MD3813800T2 (ro) 2018-06-29 2025-10-31 Incyte Corp Formulări de inhibitor al AXL/MER
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR20000070351A (ko) * 1997-01-24 2000-11-25 앨린 앤더슨 젬시타빈 유도체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
KR20000070351A (ko) * 1997-01-24 2000-11-25 앨린 앤더슨 젬시타빈 유도체

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KR 제10-2000-70351호.*
US 제5362718호.*

Also Published As

Publication number Publication date
WO2002080975A1 (en) 2002-10-17
NO20034433L (no) 2003-11-25
HUP0304093A3 (en) 2008-08-28
DE60228699D1 (de) 2008-10-16
NO20034433D0 (no) 2003-10-03
ATE406892T1 (de) 2008-09-15
JP2004525950A (ja) 2004-08-26
EP1385551A1 (en) 2004-02-04
MXPA03009092A (es) 2004-02-12
ES2312568T3 (es) 2009-03-01
SI1385551T1 (sl) 2008-12-31
SG152906A1 (en) 2009-06-29
EP1385551B1 (en) 2008-09-03
EA010184B1 (ru) 2008-06-30
NZ540047A (en) 2007-01-26
BR0208627A (pt) 2004-03-09
KR20040007491A (ko) 2004-01-24
CN1309421C (zh) 2007-04-11
PL363991A1 (en) 2004-11-29
IL157898A0 (en) 2004-03-28
HUP0304093A2 (hu) 2004-04-28
EA200301091A1 (ru) 2004-02-26
PT1385551E (pt) 2008-11-03
CN1545419A (zh) 2004-11-10
CA2442849A1 (en) 2002-10-17
HK1060062A1 (en) 2004-07-30
AU2007242958A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
KR100862178B1 (ko) 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물
US20060035904A1 (en) Antineoplastic combinations
US20030008923A1 (en) Antineoplastic combinations
RU2632104C2 (ru) Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
AU2008202690A1 (en) Antineoplastic combination
US7189735B2 (en) Use of CCI-779 as an antineoplastic agent
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
AU2009309616A1 (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
US20050187184A1 (en) Antineoplastic combinations
ZA200309816B (en) Antineoplastic combinations
AU2002259309A1 (en) Antineoplastic combinations
AU2002257123A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
HK1060062B (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20111002

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20111002

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000